Manatuck Hill Partners’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
JAIC
Manatuck Hill Partners's STLN Position: Q3 2026 in Review
Manatuck Hill Partners increased its Starling Oncology (STLN) stake by 17% in Q3 2026, buying an estimated $448K and bringing the position to 525,000 shares worth $3.32M. The position accounts for 1.13% of the portfolio, ranked #26.
Manatuck Hill Partners first reported a position in STLN in Q1 2025 and has held it in 5 quarters since. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.
- Manatuck Hill Partners held 525,000 shares of Starling Oncology worth $3.32M as of Q3 2026.
- Manatuck Hill Partners bought 75,000 Starling Oncology shares in Q3 2026, an estimated $448K.
- Starling Oncology made up 1.13% of Manatuck Hill Partners's portfolio in Q3 2026, its #26 holding.
- Manatuck Hill Partners first reported a position in Starling Oncology in Q1 2025 and has held it in 5 quarters since.
- 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.
Based on Manatuck Hill Partners's 13F filing for Q3 2026, filed 16 Nov 2026.